title: Differential antinociceptive effects of buprenorphine and methadone in the presence of HIV-gp120.
abstract: BACKGROUND
  We showed recently that elevated brain levels of the chemokine stromal cell-derived growth factor-1α (SDF-1α/CXCL12, a ligand for the human immunodeficiency virus [HIV] co-receptor CXCR4) diminish the antinociceptive effect of morphine, but failed to influence buprenorphine-induced antinociception.
  
  
  OBJECTIVE
  Because the HIV-1 coat protein, glycoprotein 120 (gp120) T-tropic strain, binds to the same receptor as SDF-1α/CXCL12, the present experiments were designed to investigate the consequence of administering gp120 to rat brain on buprenorphine-induced antinociception in the 54°C hot plate test. For comparative purposes, the effect of gp120 on an equi-antinociceptive dose of methadone was also examined.
  
  
  METHODS
  A sterilized stainless-steel C313G guide cannula was implanted into the periaqueductal grey (PAG), a brain region critical for the processing of pain signals, and a primary site of action of many analgesics. Rats were pretreated with gp120, administered into the PAG.
  
  
  RESULTS
  The subsequent antinociception associated with methadone was diminished whereas buprenorphine-induced antinociception was unaffected. Buprenorphine thus appears to be a more effective analgesic than methadone in the presence of gp120 in the brain, a condition that is associated with HIV-related pain and infection.
authors: Center for Substance Abuse Research, Temple University School of Medicine, 3400N. Broad Street, Philadelphia, PA 19140, USA.
authors: Jonathan
authors: J
authors: Palma
authors: Alan
authors: A
authors: Cowan
authors: Ellen B
authors: EB
authors: Geller
authors: Martin W
authors: MW
authors: Adler
authors: Khalid
authors: K
authors: Benamar
references: J Virol. 2000 Jan;74(2):619-26
references: 10623723
references: Br J Anaesth. 2005 Jun;94(6):825-34
references: 15833777
references: J Neurosci Methods. 1980 Dec;3(2):129-49
references: 6110810
references: Annu Rev Immunol. 1999;17:657-700
references: 10358771
references: CNS Drug Rev. 2002 Winter;8(4):377-90
references: 12481193
references: Front Neuroendocrinol. 2001 Jul;22(3):147-84
references: 11456467
references: Immunopharmacology. 2000 Jul 20;48(2):145-56
references: 10936512
references: Brain Behav Immun. 2007 Aug;21(6):767-74
references: 17291715
references: Brain Res. 2000 Apr 7;861(1):105-16
references: 10751570
references: Brain Res. 2004 Sep 3;1019(1-2):22-7
references: 15306234
references: Drug Alcohol Depend. 2011 Apr 1;114(2-3):246-8
references: 21112161
references: Dent Econ. 1970 Dec;60(12):29-32
references: 5278416
references: J Exp Med. 1997 Aug 4;186(3):455-60
references: 9236198
references: Psychopharmacology (Berl). 1995 Jun;119(3):268-76
references: 7675960
references: J Neurosci. 2001 Jul 15;21(14):5027-35
references: 11438578
references: Drug Alcohol Depend. 2007 Apr 17;88(1):36-41
references: 17049756
references: Pain. 2004 Jul;110(1-2):385-92
references: 15275790
references: Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S13-27
references: 12738347
references: Pain Pract. 2010 Sep-Oct;10(5):428-50
references: 20492579
references: J Leukoc Biol. 2005 Dec;78(6):1204-9
references: 16204637
references: Brain Behav Immun. 2008 May;22(4):606-13
references: 18294814